Therapeutic monoclonal antibodies (mAbs) are potent new tools for a molecular targeted approach to modify the course of multiple sclerosis (MS). Besides natalizumab, which was approved in 2006 ...

Stock recommendation on SIGA Technologies affected by mpox outbreak response, diversifying into mAbs for orthopoxviruses, remains speculative buy.

Researchers suggest broadly reactive antibodies identified are likely to represent a common mechanism of acquired immunity to ...

A Golden Gate-based dual-expression vector enables rapid screening, which facilitates efficient isolation of high-affinity cross-reactive antibodies for therapeutic or diagnostic use and provides a ...

Adagene Inc. (NASDAQ:ADAG – Get Free Report) was the target of a significant decline in short interest in the month of November. As of November 15th, there was short interest totalling 1,500 shares, a ...

Nov. 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (NASDAQ: DYAI), a global biotechnology company, announced today that it has been awarded a $3 million grant from the Gates Foundation for ...

Laekna, Inc. (2105.HK) (“Laekna”), a global biotech company focused on novel drug development for metabolic and cancer ...

Monoclonal antibodies (mAbs) are nature's biological warheads, able to target and help eliminate foreign or abnormal agents from the body. In theory, replicating this powerful defense system could ...

has become a global player in human monoclonal antibody (mAb) discovery and development, and it is now a driver of the general trend in the immunotherapy space toward the use of fully human mAbs ...

Monoclonal antibodies (mAbs) have revolutionized cancer therapy due to their ability to specifically target tumor cells while ...

20% of patients had a best clinical response of SD Elotuzumab (HuLuc63), a humanized mAb CS1 High expression on the surface of MM cell lines and on plasma cells from MM patients 24 ADCC against MM ...

With the invention of hybridoma technology in 1975, monoclonal antibodies (mABs) have undergone significant advancements and ...